Natco Pharma received an order from the Assistant Commissioner (ST), Tenali, demanding a total of Rs 60 lakh under the APGST & CGST Act, 2017. The order, dated July 13, 2026, raises a demand for tax, interest, and penalty following an audit for the period from April 1, 2020, to December 17, 2024. The company stated that the matter is currently under evaluation and that it will take the appropriate course of action.

The order specifies a tax demand of Rs 21,34,729, interest of Rs 17,17,806, and a penalty of Rs 21,34,729. The authority cited a lower amount reported under the Reverse Charge Mechanism (RCM) in GSTR 3B as the reason for the violation. The disclosure was made to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Natco Pharma clarified that there is no material impact on its financial, operational, or other activities as a result of this order. The company is currently reviewing the demand and its implications before deciding on the next steps.

Natco Pharma has designated Gnanadeva Chalapathy Gudipati as Senior Vice President of Analytical Research & Development and Madhava Rao Karicherla as Vice President of Formulation Research & Development, effective July 6, 2026. The appointments aim to strengthen the company's research and development capabilities across its pharmaceutical operations, specifically within the Pharma Division, Kothur Unit.

The designations were made in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the disclosure to the stock exchanges, detailing the profiles and terms of appointment for the new senior management personnel.

Gnanadeva Chalapathy Gudipati brings experience in resolving complex technical problems and managing internal and external audits. He has been associated with Natco Pharma Limited since September 15, 2017, and previously worked with Mylan Laboratories Limited. He holds an Executive Programme in Operations Management from the Indian Institute of Management, Kozhikode, and a Master's degree in Chemistry from the Institute of Chemical Sciences, Indore.

Madhava Rao Karicherla has over 20 years of experience in global generic product development, ANDA filings, and operations management. He joined Natco Pharma Limited on November 15, 2024, and has worked with companies such as Sandoz India Private Limited, Eugia Pharma Specialities Limited, Stabicon Life Sciences, Laurus Labs Limited, Abdi Ibrahim Pharmaceuticals, Aurobindo Pharma Limited, and Ranbaxy Research Laboratories. He holds a Master's of Pharmacy from the National Institute of Pharmaceutical Education and Research, Mohali, and a Bachelor of Pharmacy from Osmania University.

The terms of appointment for both officials are as per the company's policy. The disclosure confirmed that there is no specific relationship between the appointees and the directors of the company that requires disclosure under the regulations.